The most common AEs in this study included hypertension, PPES, decreased appetite, proteinuria, and fatigue, which are well-known class effects of VEGF-targeted therapies and are consistent with the known safety profile of lenvatinib. The gene discussed is VEGFA; the disease is Hypertension.